![Nigel McCracken](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nigel McCracken
Operationeel Directeur bij
VIRAX BIOLABS GROUP LIMITED
Vermogen: 7 447 $ op 30-06-2026
Profiel
Nigel McCracken currently works at Virax Biolabs Group Ltd., as Chief Operating Officer & Director.
Dr. McCracken also formerly worked at Debiopharm International SA, as Executive Director & VP-Translational Medicine from 2014 to 2019, NuCana Plc, as COO, Senior VP-Discovery & Early Development, and BerGenBio ASA, as Chief Scientific Officer from 2021 to 2023.
Dr. McCracken received his undergraduate degree from the University of Strathclyde and graduate degree from King's College London.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 02-07-2026 | 2.533 ( 0,32% ) | 7 447 $ | 30-06-2026 |
Actieve functies van Nigel McCracken
| Bedrijven | Functie | Begin |
|---|---|---|
| VIRAX BIOLABS GROUP LIMITED | Operationeel Directeur | 01-09-2023 |
Eerdere bekende functies van Nigel McCracken
| Bedrijven | Functie | Einde |
|---|---|---|
| ONCOINVENT ASA | Hoofd Techniek/Wetenschap/O&O | 01-09-2023 |
Debiopharm International SA
 Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Directeur/Bestuurslid | 01-04-2019 |
| NUCANA PLC | Operationeel Directeur | - |
Opleiding van Nigel McCracken
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
5
Eerstegraads connecties
6
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Debiopharm International SA
Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Health Technology |
University of Strathclyde
 University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
NuCana Plc
 NuCana Plc BiotechnologyHealth Technology Develops and commercializes novel anti-cancer medicines | Health Technology |
Virax Biolabs Group Ltd.
 Virax Biolabs Group Ltd. Financial ConglomeratesFinance Develops and distributes immunology software, platform and medical devices | Finance |
